The method of obtaining iron-containing drug for the treatment and prevention of iron deficiency anemia in animals

 

(57) Abstract:

The invention relates to pharmaceutical industry and relates to a method of producing iron-containing drug for the treatment and prevention of iron deficiency anemia in animals by the interaction of organic acids with gemostimuliruyuschee properties, isolated from extracts of peat, with a hydroxide of iron (11), selected from water-soluble salts of iron (11) the deposition of the alkaline solution with the subsequent laundering of impurities with water. The invention provides a high quality product by reducing impurities ammonium sulfate. 1 PL.

The invention relates to the field of drugs and their receipt for the treatment and prevention of iron deficiency anemia in animals.

A method of obtaining water iron drug /1/ in the interaction of compounds of iron and soluble polymers that can form complexes with iron (III) when heated, and the polymer used compounds obtained by the interaction in aqueous solution of a hydroxycarboxylic acid, a polyhydric alcohol and epoxidised component with subsequent processing of the reaction products by cyanide and hydrolethalus soluble polymers, which have no gemostimuliruyuschee properties, which leads to low efficiency of the final product. In addition, the source reagents-road complexing agents and their use greatly increases the cost of the target product. The use of cyanide and epoxidised component increases the risk that the target product is toxic.

A method of obtaining iron-containing drug for the treatment and prevention of iron deficiency anemia in animals /2/, which consists in the interaction of organic acids with gemostimuliruyuschee properties, isolated from extracts of peat and water-soluble salts of divalent iron, which take in the amount equivalent to the content of carboxyl groups of humic and / or fulvic acids.

The disadvantage of this method is the significant content in the composition of the final product impurities in the form of ammonium sulfate, bring salt Mora in the production process. The presence of these impurities does not cause symptoms embryotoxic and teratogenic effects with the drug to pregnant rats at therapeutic doses, however, may adversely affect the body of sows and piglets. Ammonium sulfate application is the act of pigs, the most vulnerable to iron deficiency anemia, less than ruminant microorganisms can synthesize amino acids from non-protein nitrogen [4]. The feeding of ammonium sulfate pigs leads to their death /5/.

The inventive method of obtaining iron drug aims to eliminate the above disadvantages and is in the interaction of organic acids with gemostimuliruyuschee properties, isolated from extracts of peat, and the compound iron (II), and as compounds of iron (II) take svezheosazhdennoi hydroxide iron (II), selected from water-soluble salt of iron (II), for example salt Mora, the deposition of the alkaline solution and washed away impurities with water.

New in the present method is that to obtain the product as compounds of iron (II) apply svezheosazhdennoi hydroxide iron (II), selected by reacting salts of iron (II), for example salt Mora, and a hydroxide of an alkali metal.

The use of hydroxide of iron (II) to obtain iron-containing drug for the treatment and prevention of iron deficiency anemia in animals reduces the amount of impurities of ammonium sulfate in the final product.

The final product contains 26.9% of the impurities in the form of ammonium sulphate on the absolute dry substance of the drug, 11.5% of the gross nitrogen and 6,05% iron (II).

Example 2

Receiving iron-containing preparation according to the present method.

Salt Mora in the amount of 1.24 g (0,006 g-EQ) and containing about 0.90 g of dry matter, containing 0.09 g gross nitrogen and 0,073 g admixture of ammonium sulfate, dissolved in 40 ml of distilled water, poured to 2.29 ml of 10% sodium hydroxide solution. The resulting suspension is stirred. To the suspension is poured 200 ml of distilled water, stirred and centrifuged. Fell in the sludge suspension of iron hydroxide containing 0.28 g of dry matter, 0.01 g gross nitrogen and 0.09 g admixture of ammonium sulfate is mixed with 400 ml of the extract of peat containing are 5.36 g of dry matter (0,0 s 0,5-1 hour and leave it for two days, then the product is dried at 20 to 40°C.

The resulting product contains dry substance 1,59% impurities in the form of ammonium sulfate, to 6.88% of the gross nitrogen and is 3.08% iron (II).

Study of the effect obtained herocomplex on for iron deficiency anemia were conducted on 50 outbred white mice-females. 40 mice was simulated iron deficiency anemia (single acute loss of 30% of circulating blood). 10 animals were used as background. An hour later after blood loss and then every day, 1 time per day to mice two experimental groups were injected intragastrically through the probe herocomplex in 1% starch mucus. The positive control group were asked by the appropriate number of official drug terrordome in 1% starch mucus. The control group received only the starch mucilage.

For therapeutic adopted the dose of elemental iron 42 mg/kg

The value of the integral index (PI) was calculated by the formula /6/:

where h is the number of terms measurement;

Mij is the value of the j-th index in the i-th term of measurement;

Mj(0) is the initial value.

The table presents the effectiveness of drugs on the model taleporos admixture of ammonium sulfate as an effective dose of the drug received decreased 8.6 times relative to the prototype.

Sources of information

1. Patent USSR No. 730276, class a 61 K 27/00, publ. 25.04.80, bull. No. 15.

2. RF patent №2193565, class C 07 F 15/02, And 61 To 31/295, publ. 27.11.2002, bull. No. 39.

3. Feed. The Handbook. / Edited by M. A. Sargina. - M.: Kolos.1977, S. 368 (S. 289-292).

4. H. W. Gilman. The pig. The tutorial. Mn., Uraji. 1989, S. 311 (S. 145).

5. Chemicalization of agriculture. The scientific. - technology. the reference dictionary. Ed 2nd ed Balashev L. L., Volfkovich S. I. - M.: Nauka, 1968, 355 S.(S. 249).

6. Goldberg E. D., Digoy A. M., Khlusov I. A. the Role of the autonomic nervous system in the regulation of haematopoiesis. Tomsk, 1997, - S. 218.

The method of obtaining iron-containing drug for the treatment and prevention of iron deficiency anemia in animals, which consists in the interaction of organic acids with gemostimuliruyuschee properties, isolated from extracts of peat, and the composition of iron (11) forming a water soluble complex, characterized in that compounds of iron (11) take the hydroxide of iron (11), selected from water-soluble salts of iron (11) the deposition of the alkaline solution with the subsequent laundering of impurities with water.



 

Same patents:

The invention relates to preparations for the prevention and treatment of Pets and farm animals, as well as to maintain the microelemental composition of the feed, and can be used in animal breeding and fur farming

The invention relates to experimental medicine, may find application in radiobiological experiments, and further in clinical practice

The invention relates to organic chemistry and pharmacology, and relates new connection - 1-(1,1-dissociator-3)-2-morpholinobenzenediazonium hydrochloride, increasing resistance to acute hypoxia with hypercapnia

The invention relates to biotechnology and is used for the preparation of recombinant human erythropoietin (EPO)
The invention relates to medicine, surgery and intensive care, to a method of replacement of massive blood loss of any Genesis

The invention relates to medicine, in particular to the pharmaceutical industry, and can be used as adjuvant iron deficiency anemia

The invention relates to medicine, in particular Infectology and Hematology

The invention relates to pharmacology and medicine, namely to receive the preformed stable recombinant erythropoietin, which can be used to treat various anemic conditions

The invention relates to pharmaceutical compositions that increase fetal hemoglobin of the patient or accelerating differentiation of cells containing an effective amount of butyrate precursor drug of formula I in which a and D are independently from each other selected from the group comprising hydrogen, barbiecollector.com or C(1-4) straight or branched alkyl, S(2-4), straight or branched alkenyl or quinil, which may be independently substituted by hydroxy, alkoxy, carboxylation, alkylamides and so on, provided that a and D are not both hydrogen, R is oxygen, NH, NC(1-5) alkyl straight or branched chain or NHС(2-5)of alkenyl straight or branched chain, any of which may be optionally substituted by a residue of carbocycle or heterocycle, Z is hydrogen, C(1-4) alkyl straight or branched chain, With(2-4) alkenyl or quinil straight or branched chain, carbocyclic or heterocyclic residue and so on, and each stereogenic carbon atom can be R or S configuration, and pharmaceutically acceptable adjuvant or carrier

The invention relates to veterinary

The invention relates to preparations for the prevention and treatment of Pets and farm animals, as well as to maintain the microelemental composition of the feed, and can be used in animal breeding and fur farming

The invention relates to veterinary medicine, pharmacology, biology

The invention relates to animal breeding and fur farming

The invention relates to containing certain monoalkyl esters of fumaric acid in the form of salts or the free acid individually or in combination with dialkylamino for the treatment of arthritis or multiple sclerosis, as well as reactions "graft versus host"

Medical center // 2194523
The invention relates to medicine and relates to compositions for the prevention of nervous disorders and asthenic States of different etiology and resolve emotional or functional disorders caused by these conditions
The invention relates to agriculture

FIELD: pharmaceutical engineering; medical engineering.

SUBSTANCE: method involves carrying out nuclear magnetic resonance tomography of human or animal blood circulation system containing chelating ion complexes of bivalent and valence three paramagnetic metals of (I)X-L-Y formula, where X is the polyamide carbonyl ligand residue and Y is the gallic acid derivative, .

EFFECT: high accuracy of diagnosis.

28 cl

Up!